An observational study in Geriatric, Parkinsons Disease (PD) and Progressive Supranuclear Palsy(PSP), sponsored by University of Kiel. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by University of Kiel · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 264 studies in Parkinson Disease with a site in Germany — 41 open to participants now, 53 under way, 2 of them phase 3. Parkinson Disease · Germany.
Among the 264 studies in Parkinson Disease with a site in Germany, this one is the 19th largest by planned enrollment of the 64 observational ones that give a count, is one of 12 that started in 2025, is one of 64 observational ones, reaches primary completion later than 17 of the 52 other live ones, and was the 249th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →41 of the 264 studies in Parkinson Disease with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Tuebingen · Sites in Germany, France, Italy and 4 more countries
Ages 35–80
MODAG GmbH · Sites in Germany
Ages 50–75 · Healthy volunteers
H. Lundbeck A/S · Sites in Germany, United States, Czechia and 1 more country
Ages 40–85
University Hospital Muenster · Sites in Germany
Ages 18+
Integrative Research Laboratories AB · Sites in Germany, Bulgaria, Poland and 1 more country
Ages 50–90
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
264 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 53 · Phase 3 65 · Phase 4 19
First in 2001; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 106 across the 198 interventional studies, 195 across the 64 observational. Of the 186 that completed or were terminated, 73 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
173 of 264 have an industry lead sponsor. The 10 most frequent:
University of Kiel is the lead sponsor of 26 studies on the registry; 7 are open to participants now.
University of Kiel has 6 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Parkinson Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07134634Parkinson's Clinic in Beelitz-HeilstattenEffect of a Vibrating Therapy Ball on Tremor and Daily Activities in Patients With Different Tremor Syndroms | 2026-11 |
| NCT06580977Heidelberg UniversityExploring the Effects of Exercise on Memory and Cognition in Parkinson´s Disease | 2026-12 |
| NCT07141719University of KielCollection of Digital Parameters From Parts of the Neurological Examination Using an Eye Tracker | 2026-12-31 |
| NCT06602193Denali Therapeutics Inc.Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | 2027-03 |
| NCT06993571Universitätsklinikum Hamburg-EppendorfCerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor | 2027-03-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 264 studies in Parkinson Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The neurological examination (NE) is a cornerstone of clinical neurology, with ocular motor assessment being a key component. Technology offers an opportunity to augment and standardize parts of the NE. Eye-tracking systems provide objective quantitative data on eye movements by continuously tracking the eye over time. This data can be used to derive parameters like saccadic latency, gaze velocity, and fixation stability with a precision that is impossible to achieve through human observation by neurologists. The integration of such technology could enhance the traditional NE.
Before such technology can be widely adopted, its feasibility and acceptability in a clinical population must be established. The primary purpose of this study is to assess the usability of a novel eye-tracking system from the patient's perspective when used in a clinical settings. A secondary purpose is to determine if quantitative data from the eye-tracker correlate with the findings of the traditional clinical neurological examination and to explore whether eye-tracking can provide additional, complementary information not typically captured by standard clinical assessment.
To achieve these aims, the study will assess several outcome measures. The primary outcome measure is the Usability of the Eye-Tracking System, which will be measured using the System Usability Scale (SUS).
Beyond the primary objectives, this study will investigate two secondary objectives.
The first involves assessing the relationship between quantitative eye-tracking parameters and clinical ocular motor assessment. Specifically, the investigators will analyze objective, numerical data obtained from eye-tracking systems and the clinician's subjectively graded assessment of ocular movements derived from the standard neurological examination.
The second is the exploratory analysis of novel eye-tracking biomarkers. This involves quantifying and analyzing eye-tracking parameters not typically assessed during a routine NE. For example, the dynamics of the pupillary light reflex or the frequency of microsaccades. The aim is to identify potential digital biomarkers that could provide additional objective insights into ocular motor function and neurological status.
Adult volunteers hospitalized on the wards and outpatient areas of the Department of Neurology
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients admitted to the wards and the outpatient clinics of the Department of Neurology, Universitätsklinikum Schleswig-Holstein (UKSH), Campus Kiel
System Usability Scale (SUS)
The System Usability Scale (SUS) is a validated and widely used 10-item questionnaire designed to assess the subjective usability of a system-in this case, a wearable eye-tracking device. Each item is rated on a 5-point Likert scale from Strongly Disagree (1) to Strongly Agree (5). The SUS yields a single score ranging from 0 to 100, where higher scores indicate greater perceived usability. A score of 68 is generally considered average; scores above 80 indicate high usability, while scores below 50 suggest usability concerns. Usability, in this context, includes perceptions of comfort, system complexity, ease of use, learnability, and willingness to use the system regularly or independently. Participants complete the SUS immediately after using the eye-tracker in a controlled session.
Time frame: Baseline (single session, approx. 2-3 hour per participant)
Vestibulo-ocular reflex (VOR)
The vestibulo-ocular reflex (VOR) is measured using the eye-tracker during sitting, standing, and walking. Participants' heads are passively rotated at 100-300 °/s, and the ratio of eye velocity to head velocity (velocity gain) is calculated. A gain of 1.0 indicates perfect VOR function; 0 indicates complete absence.
Time frame: Baseline (single session, approx. 2-3 hour per participant)
Vestibulo-ocular reflex suppression (VORS)
Vestibulo-ocular reflex suppression (VORS) is assessed using a head-fixed target. Reflexive eye drift opposite to head movement is measured in sitting, standing, and walking. VORS is calculated as the ratio of eye position to head position (position gain). A score of 100% indicates full expression of the vestibuloocular reflex (VOR) (no suppression), while 0% indicates complete suppression.
Time frame: Baseline (single session, approx. 2-3 hour per participant)
Saccades velocity
Saccades are rapid eye movements used to fixate on new visual targets. Using the eye-tracker, saccade velocity (°/s) is recorded and analyzed to detect abnormalities such as slowed or dysmetric movements.
Time frame: Baseline (single session, approx. 2-3 hour per participant)
Glabella reflex
The glabellar reflex is assessed by repeated tapping of the participant's glabella. Normally, the blink response habituates after 3-5 taps. Persistent blinking beyond this suggests reduced frontal lobe inhibition. The total number of blinks is recorded.
Time frame: Baseline (single session, approx. 2-3 hour per participant)
Pupillary reflex
The pupillary light reflex is assessed by alternately illuminating each eye. An eye-tracker records pupil size, shape, latency, and constriction velocity. Asymmetric responses may indicate neurological deficits. Differences between eyes are quantified, with thresholds based on clinical norms.
Time frame: Baseline (single session, approx. 2-3 hour per participant)
Pupil size at rest
Resting pupil size is measured and compared to normative thresholds. Values outside defined ranges are classified as mydriasis (dilated), miosis (constricted), or normal.
Time frame: Baseline (single session, approx. 2-3 hour per participant)
Nystagmus at rest, slow phase
Nystagmus is characterized by alternating slow and fast eye movements. At rest, the slow phase velocity (°/s) is recorded during gaze to the left and right using the eye-tracker.
Time frame: Baseline (single session, approx. 2-3 hour per participant)
Skew deviation
Skew deviation is assessed using alternate eye cover testing while the participant fixates on a target. A positive result is indicated by vertical correction movements (geotropic/apogeotropic). The presence and magnitude of deviation are evaluated based on predefined thresholds.
Time frame: Baseline (single session, approx. 2-3 hour per participant)
Smooth pursuit (SP) number of saccades
Smooth pursuit (SP) is an eye movement in which a moving object is tracked by the eyes without moving the head. The tracking can be saccadic, i.e. jerky, or significantly impaired or incomplete in certain directions, such as upwards. Here, too, the investigators digitally record the extent of the eye movement during neurological examination. A disturbance of the SP is indicated by the presence of correction Saccades, which are recorded digitally. As the corrective saccade is a physiological process, the saccade is preceded by a slow phase. During this slow phase, the eye The frequency of the saccades in a time unit is indicated and, if possible, the nature and amplitude. Threshold values for this result from a comparison with the clinical examination and the gestural impression. The investigators measure the number of correction saccades per second as a measure of ability to maintain smooth pursuit.
Time frame: Baseline (single session, approx. 2-3 hour per participant)
Smooth pursuit (SP) saccade amplitude
The amplitude of the correction saccades, for example in °, during smooth pursuit (SP) also provides information about how saccades can be performed. Together with the number of saccades, it can provide information about the role that the ability to initiate and perform saccades plays during SP. Saccades may play a different role during SP than during gaze shifts. The mean amplitude of the saccades is determined.
Time frame: Baseline (single session, approx. 2-3 hour per participant)
Smooth pursuit (SP) slow phase velocity
The saccades during smooth pursuit (SP) are preceded by a slow phase, the speed of which can be determined. The investigators calculate the mean of all slow phases in °/s.
Time frame: Baseline (single session, approx. 2-3 hour per participant)
Nystagmus at rest, quick phase
Nystagmus is characterized by alternating slow and fast eye movements. The fast phase is expressed as a saccade, which is recorded and measured in degree.
Time frame: Baseline (single session, approx. 2-3 hour per participant)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Kiel